Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.36 |
| ▸ | CCKAR | P32238 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032084 | 1.00 | GLP1R (0.53) | GLP1RLPAR3TLR2LPAR1CCKAR | |
| SCHEMBL26032093 | 0.99 | GLP1R (0.51) | GLP1RLPAR3TLR2LPAR1NOD1 | |
| SCHEMBL26032229 | 0.89 | GLP1R (0.39) | GLP1RLPAR1 | |
| SCHEMBL26032116 | 0.81 | HDAC1 (0.35) | GLP1RLPAR1 | |
| SCHEMBL26032121 | 0.77 | ZDHHC20 (0.36) | GLP1R | |
| SCHEMBL21087314 | 0.77 | GLP1R (0.61) | GLP1RFOLH1 | |
| SCHEMBL16921665 | 0.76 | GLP1R (0.36) | GLP1RTLR2FOLH1 | |
| SCHEMBL21087028 | 0.75 | GLP1R (0.56) | GLP1RFOLH1 | |
| SCHEMBL22923670 | 0.74 | GLP1R (0.73) | GLP1RLPAR3TLR2LPAR1NOD1 | |
| SCHEMBL26257845 | 0.74 | GLP1R (0.64) | GLP1RLPAR3TLR2LPAR1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | GLP1R 1683/4885LPAR3 1763/4885TLR2 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.